Cost–effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy

Pegylated liposomal doxorubicin in the management of ovarian cancer

(2016) Gabriella Ferrandina   Therapeutics and Clinical Risk Management

Assessing the need for quality-adjusted cost–effectiveness studies of nanotechnological cancer therapies

(2013) Rita Bosetti et al.   Nanomedicine

Current Methodological Issues in the Economic Assessment of Personalized Medicine

(2013) Lieven Annemans et al.   VALUE IN HEALTH

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery

(2010) Fabienne Danhier et al.   JOURNAL OF CONTROLLED RELEASE

Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes

(2010) Ioannis S. Vizirianakis   Nanomedicine-Nanotechnology Biology and Medicine

What can we learn from a cross-country comparison of the costs of child delivery?

(2008) Martine M. Bellanger et al.   HEALTH ECONOMICS

Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer

(2008) Gabriella Ferrandina et al.   JOURNAL OF CLINICAL ONCOLOGY